Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 873-881

  Moody, Terry W ^a   Osefo, Nauramy ^a   Nuche Berenguer, Bernardo ^b   Ridnour, Lisa ^a   Wink, David ^a   Jensen, Robert T ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACETYLCYSTEINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPHENYLIODONIUM SALT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; ILOMASTAT; MITOGEN ACTIVATED PROTEIN KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHOLIPASE C; PROTEIN ANTIBODY; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA ANTIBODY; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; TUMOR CELLS, CULTURED; TYROSINE;

EID: 84861549027     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190033     Document Type: Article

References (37)

1. Arimura A (1992) Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept 37:287-303.
2. Bhola NE and Grandis JR (2008) Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 13:1857-1865. (Pubitemid 351599738)
3. Buscail L, Cambillau C, Seva C, Scemama JL, De Neef P, Robberecht P, Christophe J, Susini C, and Vaysse N (1992) Stimulation of rat pancreatic tumoral AR4-2J cell proliferation by pituitary adenylate cyclase-activating peptide. Gastroenterology 103:1002-1008.
4. Cattaneo F, Iaccio A, Guerra G, Montagnani S, and Ammendola R (2011) NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells. Free Radic Biol Med 51:1126-1136.
5. Draoui M, Hida T, Jakowlew S, Birrer M, Zia F, and Moody TW (1996) PACAP stimulates c-fos mRNAs in small cell lung cancer cells. Life Sci 59:307-313. (Pubitemid 26232868)
6. Germano PM, Lieu SN, Xue J, Cooke HJ, Christofi FL, Lu Y, and Pisegna JR (2009) PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells. J Mol Neurosci 39:391-401.
7. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, et al. (2006) Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12:7117-7125. (Pubitemid 44974512)
8. Landi L and Cappuzzo F (2011) Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. Nat Rev Clin Oncol 8:571-573.
9. Leyton J, Coelho T, Coy DH, Jakowlew S, Birrer MJ, and Moody TW (1998) PACAP(6-38) inhibits the growth of prostate cancer cells. Cancer Lett 125:131-139. (Pubitemid 28151920)
10. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, and Grandis JR (2003) Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22:6183-6193. (Pubitemid 37281648)
11. Lutz EM, Ronaldson E, Shaw P, Johnson MS, Holland PJ, and Mitchell R (2006) Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Mol Cell Neurosci 31:193-209. (Pubitemid 43214530)
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139. (Pubitemid 38637993)
13. May V, Lutz E, MacKenzie C, Schutz KC, Dozark K, and Braas KM (2010) Pituitary adenylate cyclase-activating polypeptide (PACAP)/PAC1HOP1 receptor activation coordinates multiple neurotrophic signaling pathways: Akt activation through phosphatidylinositol 3-kinase γ and vesicle endocytosis for neuronal survival. J Biol Chem 285:9749-9761.
14. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, and Coy DH (1989) Isolation of a novel 38-residue hypothalamic polypeptide which stimulated adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567-574. (Pubitemid 19269770)
15. Moody TW, Berna MJ, Mantey S, Sancho V, Ridnour L, Wink DA, Chan D, Giaccone G, and Jensen RT (2010) Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol 637:38-45.
16. Moody TW, Chan D, Fahrenkrug J, and Jensen RT (2003) Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 9:495-509. (Pubitemid 36131740)
17. Moody TW and Jensen RT (2006) VIP and PACAP as autocrine growth factors in breast and lung cancer, in Handbook of Biologically Active Peptides (Kastin A ed) pp 493-498, Elsevier Academic Press, Amsterdam.
18. Moody TW, Leyton J, Casibang M, Pisegna J, and Jensen RT (2002) PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regul Pept 109:135-140. (Pubitemid 35292404)
19. Moody TW, Leyton J, and Jensen RT (2012) Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin. J Mol Neurosci 46:68-74.
20. Moody TW, Zia F, Bitar K, and Coy DH(1994) PACAP(6-38) is a PACAP type I receptor antagonist on small cell lung cancer cells, in VIP, PACAP and Related Regulatory Peptides: From Molecular Biology to Clinical Applications (Rosselin G ed) pp527-534, World Scientific Publishing Co., Singapore.
21. Moody TW, Zia F, and Makheja A (1993) Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells. Peptides 14:241-246.
22. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500. (Pubitemid 38720929)
23. Pisegna JR, Leyton J, Coelho T, Hida T, Jakowlew S, Birrer M, Fridkin M, Gozes I, and Moody TW (1997) PACAP hybrid: a new PACAP receptor antagonist. Life Sci 61:631-639. (Pubitemid 27303937)
24. Pisegna JR and Wank SA (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci U S A 90:6345-6349. (Pubitemid 23191512)
25. Pisegna JR and Wank SA (1996) Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 271:17267-17274. (Pubitemid 26244284)
26. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, and Laissue JA (2000) Vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60:3105-3112. (Pubitemid 30395841)
27. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967.
28. Sekido Y, Fong KM, and Minna JD (2005) Molecular biology of lung cancer, in Cancer: Principles and Practice of Oncology (DeVita VT, Helman S, Rosenberg SA eds) pp 745-752, Lippincott Williams and Wilkins, Philadelphia.
29. Sherwood NM, Krueckl SL, and McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21:619-670. (Pubitemid 32113287)
30. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170-175. (Pubitemid 23282064)
31. Ushiyama M, Ikeda R, Sugawara H, Yoshida M, Mori K, Kangawa K, Inoue K, Yamada K, and Miyata A (2007) Differential intracellular signaling through PAC1 isoforms as a result of alternative splicing in the first extracellular domain and the third intracellular loop. Mol Pharmacol 72:103-111. (Pubitemid 46998529)
32. Ushiyama M, Ikeda R, Yoshida M, Mori K, Kangawa K, Sugawara H, Inoue K, Yamada K, and Miyata A (2010) Alternative splicing of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor contributes to function of PACAP-27. J Mol Neurosci 42:341-348.
33. Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, and Prieto JC (2009) Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol Cell Endocrinol 302:41-48.
34. Valdehita A, Carmena MJ, Bajo AM, and Prieto JC (2012) RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol 348:241-246.
35. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, et al. (2009) Pituitary adenylate cyclaseactivating polypeptide and its receptors: 20 years after the discovery. Pharm Rev 61:283-357.
36. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, and Grandis JR (2004) SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64:6166-6173. (Pubitemid 39129418)
37. Zia F, Fagarasan M, Bitar K, Coy DH, Pisegna JR, Wank SA, and Moody TW (1995) PACAP receptors regulate the growth of non-small cell lung cancer cells. Cancer Res 55:4886-4891.